Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Effectiveness of Once-weekly Compared with Thrice-weekly Subcutaneous Epoetin Alpha for the Treatment of Chemotherapy-induced Anemia

항암치료로 인한 빈혈의 치료에서 Epoetin Alpha 주일회요법과 주삼회요법의 약효 비교 연구

  • Lee, Yoon-Duck (Department of Pharmacy, National Cancer Center) ;
  • Kim, Kyung-Im (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Kim, Young-Ju (Department of Pharmacy, National Cancer Center) ;
  • Shin, Wan-Gyoon (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Oh, Jung-Mi (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
  • Received : 2009.10.25
  • Accepted : 2009.12.20
  • Published : 2009.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : 본 연구의 목적은 항암치료로 인한 빈혈환자의 치료에서 epoetin alpha (rHuEPO) 피하주사 시, 주일회 요법과 주삼회요법의 헤모글로빈(hemoglobin, Hb) 상승 효과를 비교하는 것이다. Methods : 본 연구는 1999년 3월부터 2005년 3월까지 국립암센터에서 항암치료로 인한 빈혈로 epoetin alpha를 투여 받은 환자를 대상으로 의무기록의 자료를 후향적으로 수집하여 분석하였다. 연구에 포함된 환자는 rHuEPO 10,000 IU 주삼회투여군(n = 127)과 20,000 IU 주일회투여군(n = 81)으로 구분되었으며, 이들은 필요에 따라 경구용 철분보조제를 섭취하였다. Epoetin alpha 치료 시작 후 최대 8주까지 2주 간격으로 Hb 수치변화를 분석하였다. Results : 치료 시작 시점의 rHuEPO 10,000 IU 주삼회투여군과 20,000 IU 주일회투여군의 평균 Hb수치는 유사하였 다 (9.4 g/dL vs. 9.7 g/dL). Epoetin alpha 치료 후 8주까지 두 그룹간의 헤모글로빈 수치의 상승 정도에는 유의한 차이가 없었다 ($1.57{\pm}1.39$ g/dL vs. $1.68{\pm}1.35$ g/dL, p=0.59). 또한 경구용 철분보조제 투여여부, cisplatin 포함 항암제 투여여부 및 성별에 따른 군의 분류에 있어서도 rHuEPO 10,000 IU 주삼회투여군과 20,000 IU 주일회투여군의 평균 Hb 상승수치는 유의한 차이를 보이지 않았다. Conclusion : 한국인에서 항암치료로 인한 빈혈의 치료 시에 rHuEPO 20,000 IU 주일회투여 용법은 10,000 IU 주 삼회투여 용법과 유사한 Hb 상승효과를 가진다.

Keywords

References

  1. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994; 21: 3-8.
  2. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25: 43-6.
  3. Henry DH. The evolving role of epoetin alfa in cancer therapy. Oncologist 2004; 9: 97-107. https://doi.org/10.1634/theoncologist.9-1-97
  4. Goodnough LT. Erythropoietin therapy versus red cell transfusion. Curr Opin Hematol 2001; 8: 405-10. https://doi.org/10.1097/00062752-200111000-00015
  5. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303-20. https://doi.org/10.1182/blood-2002-06-1767
  6. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-34. https://doi.org/10.1200/JCO.1997.15.3.1218
  7. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82. https://doi.org/10.1200/JCO.2001.19.11.2875
  8. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74. https://doi.org/10.1200/JCO.2001.19.11.2865
  9. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Jr., Glaspy J. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 2002; 3: 45-51. https://doi.org/10.3816/CBC.2002.n.011
  10. FDA label information on ESA: http://wwwfdagov/cder/ drug/infopage/RHE/.
  11. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57: 411- 8. https://doi.org/10.1007/s002280100324
  12. Ortho Biotech Products LP. $Procrit^{\circledR}$ (epoetin alfa) prescribing information. Ortho Biotech Products, Raritan, NJ (March) 2007.
  13. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-9. https://doi.org/10.1038/ki.1996.487
  14. Haurani FI, Green D, Young K. Iron Absorption in Hypoferremia. Am J Med Sci 1965; 249: 537-47. https://doi.org/10.1097/00000441-196505000-00007
  15. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-8.
  16. Puglisi F, Deroma L, Russo S, et al. Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients. Crit Rev Oncol Hematol 2009; 69: 175-82. https://doi.org/10.1016/j.critrevonc.2008.07.010
  17. Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006; 11: 409-17. https://doi.org/10.1634/theoncologist.11-4-409
  18. Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatinassociated anemia. Oncology 1995; 52: 422-6. https://doi.org/10.1159/000227501
  19. Massa E, Madeddu C, Lusso MR, Gramignano G, Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 2006; 57: 175-82. https://doi.org/10.1016/j.critrevonc.2005.06.001
  20. Heras P, Argyriou AA, Papapetropoulos S, Karagiannis S, Argyriou K, Mitsibounas D. The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients. Eur J Cancer Care (Engl) 2005; 14: 108-12. https://doi.org/10.1111/j.1365-2354.2005.00571.x
  21. Lee YK, Kim SG, Seo JW, et al. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study. Nephrol Dial Transplant 2008; 23: 3240-6. https://doi.org/10.1093/ndt/gfn255